Investigation into the Effect of Photodynamic Therapy and Cisplatin on the Cervical Cancer Cell Line (A2780) Photodynamic Therapy and Cisplatin on A2780
Journal of Lasers in Medical Sciences,
Vol. 11 No. Supplement (2020),
30 December 2020
,
Page S85-S91
Abstract
Introduction: Cervical cancer is recognized as one of the major causes of mortality among elderly women. Although there are several different therapeutic worldwide guidelines, many researchers have focused on screening new methodologies and technologies to elevate the efficiency of cervical cancer treatment. The simultaneous use of photodynamic therapy (PDT) along with chemotherapy as cisplatin has achieved good aims in the treatment of cervical cancer.
Methods: A2780 cells were treated with cisplatin, photodynamic progress (laser with methylene blue as a photosensitizer compound) and a combination of cisplatin and PDT. The lithic effect of the laser, methylene blue and their combination and the IC50 value of cisplatin were calculated for each group. The amount of malondialdehyde (MDA) as membrane lipid peroxidation product and released lactate dehydrogenase was measured in the medium. The toxicity of each agent was evaluated by the MTT technique.
Results: The results show that a combination of PDT and chemotherapeutic agent cisplatin caused a twofold decrease in viable cervical cancer cells compared to each therapeutic progress. The combination of both laser therapy and cisplatin enhanced cancer cell membrane disruption by increased membrane lipid peroxidation and apoptotic enzyme activation by the elevation of lactate dehydrogenase activity.
Conclusion: The results indicated that cisplatin combined with PDT had a greater therapeutic effect on A2780 as a cervical cancer cell line. Therefore, PDT in combination with chemotherapy enhances the effectiveness of chemotherapeutic agents by the disruption of the cancer cell membrane and switching the apoptosis progress with less adverse effects.
- Cancer
- Chemotherapy
- Photodynamic therapy
- Cisplatin
- Cervical cancer
- Laser.
How to Cite
References
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. doi: 10.3322/caac.21492.
Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284-96. doi: 10.3322/caac.21456.
Tatarov I, Panda A, Petkov D, Kolappaswamy K, Thompson K, Kavirayani A, et al. Effect of magnetic fields on tumor growth and viability. Comp Med. 2011;61(4):339-45.
Kearney N, Richardson A, editors. Nursing patients with cancer: principles and practice. Edinburgh : Elsevier/Churchill Livingstone; 2006.
Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM, Tattersall MH. On the receiving end—patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol. 1983;19(2):203-8. doi: 10.1016/0277-5379(83)90418-2.
Cohen SM, Lippard SJ. Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol. 2001;67:93-130. doi: 10.1016/s0079-6603(01)67026-0.
Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364-78. doi: 10.1016/j.ejphar.2014.07.025.
Torigoe T, Izumi H, Ishiguchi H, Yoshida Y, Tanabe M, Yoshida T, et al. Cisplatin resistance and transcription factors. Curr Med Chem Anticancer Agents. 2005;5(1):15-27. doi: 10.2174/1568011053352587.
Jamieson ER, Lippard SJ. Structure, recognition, and processing of cisplatin−DNA adducts. Chem Rev. 1999;99(9):2467-98. doi: 10.1021/cr980421n.
Mandic A, Hansson J, Linder S, Shoshan MC. Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem. 2003;278(11):9100-6. doi: 10.1074/jbc.M210284200.
Wang X, Martindale JL, Holbrook NJ. Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem. 2000;275(50):39435-43. doi: 10.1074/jbc.M004583200.
Stordal B, Davey M. Understanding cisplatin resistance using cellular models. IUBMB Life. 2007;59(11):696-9. doi: 10.1080/15216540701636287.
Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007;33(1):9-23. doi: 10.1016/j.ctrv.2006.09.006.
Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. Mutat Res. 2001;478(1-2):23-43. doi: 10.1016/S0027-5107(01)00141-5.
Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: a review. Am J Med Sci. 2007;334(2):115-24. doi: 10.1097/MAJ.0b013e31812dfe1e.
dos Santos NA, Martins NM, Curti C, Pires Bianchi ML, dos Santos AC. Dimethylthiourea protects against mitochondrial oxidative damage induced by cisplatin in liver of rats. Chem Biol Interact. 2007;170(3):177-86. doi: 10.1016/j.cbi.2007.07.014.
Al-Majed AA, Sayed-Ahmed MM, Al-Yahya AA, Aleisa AM, Al-Rejaie SS, Al-Shabanah OA. Propionyl-L-carnitine prevents the progression of cisplatin-induced cardiomyopathy in a carnitine-depleted rat model. Pharmacol Res. 2006;53(3):278-86. doi: 10.1016/j.phrs.2005.12.005.
Goldberg A, Altaras MM, Mekori YA, Beyth Y, Confino-Cohen R. Anaphylaxis to cisplatin: diagnosis and value of pretreatment in prevention of recurrent allergic reactions. Ann Allergy. 1994;73(3):271-2.
Daniell MD, Hill JS. A history of photodynamic therapy. Aust N Z J Surg. 1991;61(5):340-8. doi: 10.1111/j.1445-2197.1991.tb00230.x.
Dougherty TJ, Grindey GB, Fiel R, Weishaupt KR, Boyle DG. Photoradiation therapy. II. Cure of animal tumors with hematoporphyrin and light. J Natl Cancer Inst. 1975;55(1):115-21. doi: 10.1093/jnci/55.1.115.
Babilas P, Landthaler M, Szeimies RM. Photodynamic therapy in dermatology. Eur J Dermatol. 2006;16(4):340-8.
Lipson RL, Baldes EJ, Olsen AM. Hematoporphyrin derivative: a new aid for endoscopic detection of malignant disease. J Thorac Cardiovasc Surg. 1961;42(5):623-9. doi: 10.1016/S0022-5223(19)32560-7.
Hsi RA, Rosenthal DI, Glatstein E. Photodynamic therapy in the treatment of cancer: current state of the art. Drugs. 1999;57(5):725-34. doi: 10.2165/00003495-199957050-00005.
van Meerloo J, Kaspers GJ, Cloos J. Cell sensitivity assays: the MTT assay. Methods Mol Biol. 2011;731:237-45. doi: 10.1007/978-1-61779-080-5_20.
Martin RB. Hydrolytic Equilibria and N7 versus N1 binding in purine nucleosides of cis-Diamminedichloroplatinum (II) palladium (II) as a guide to platinum (II) reactions at equilibrium. In: Lippard SJ, editor. Platinum, gold, and other metal chemotherapeutic agents. Washington, D.C: American Chemical Society; 1983. p. 231-44.
Reedijk J, Lohman PH. Cisplatin: synthesis, antitumour activity and mechanism of action. Pharm Weekbl Sci. 1985;7(5):173-80. doi: 10.1007/BF02307573.
Fuertes MA, Castilla J, Alonso C, Pérez JM. Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr Med Chem. 2003;10(3):257-66. doi: 10.2174/0929867033368484.
Tata DB, Waynant RW. Laser therapy: a review of its mechanism of action and potential medical applications. Laser Photon Rev. 2011;5(1):1-12. doi: 10.1002/lpor.200900032.
Hunt CR, Sim JE, Sullivan SJ, Featherstone T, Golden W, Kapp-Herr CV, et al. Genomic instability and catalase gene amplification induced by chronic exposure to oxidative stress. Cancer Res. 1998;58(17):3986-92.
del Bello B, Paolicchi A, Comporti M, Pompella A, Maellaro E. Hydrogen peroxide produced during γ-glutamyl transpeptidase activity is involved in prevention of apoptosis and maintainance of proliferation in U937 cells. FASEB J. 1999;13(1):69-79. doi: 10.1096/fasebj.13.1.69.
Burdon RH. Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. Free Radic Biol Med. 1995;18(4):775-94. doi: 10.1016/0891-5849(94)00198-s.
Qian Y, Luo J, Leonard SS, Harris GK, Millecchia L, Flynn DC, et al. Hydrogen peroxide formation and actin filament reorganization by Cdc42 are essential for ethanol-induced in vitro angiogenesis. J Biol Chem. 2003;278(18):16189-97. doi: 10.1074/jbc.M207517200.
Polytarchou C, Hatziapostolou M, Papadimitriou E. Hydrogen peroxide stimulates proliferation and migration of human prostate cancer cells through activation of activator protein-1 and up-regulation of the heparin affin regulatory peptide gene. J Biol Chem. 2005;280(49):40428-35. doi: 10.1074/jbc.M505120200.
López-Lázaro M. Dual role of hydrogen peroxide in cancer: possible relevance to cancer chemoprevention and therapy. Cancer Lett. 2007;252(1):1-8. doi: 10.1016/j.canlet.2006.10.029.
Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, et al. Photodynamic therapy. J Natl Cancer Inst. 1998;90(12):889-905. doi: 10.1093/jnci/90.12.889.
Alberts DS, Garcia D, Mason-Liddil N. Cisplatin in advanced cancer of the cervix: an update. Semin Oncol. 1991;18(1 Suppl 3):11-24.
Buxton EJ, Meanwell CA, Hilton C, Mould JJ, Spooner D, Chetiyawardana A, et al. Combination bleomycin, ifosfamide, and cisplatin chemotherapy in cervical cancer. J Natl Cancer Inst. 1989;81(5):359-61. doi: 10.1093/jnci/81.5.359.
Crescenzi E, Chiaviello A, Canti G, Reddi E, Veneziani BM, Palumbo G. Low doses of cisplatin or gemcitabine plus Photofrin/photodynamic therapy: Disjointed cell cycle phase-related activity accounts for synergistic outcome in metastatic non-small cell lung cancer cells (H1299). Mol Cancer Ther. 2006;5(3):776-85. doi: 10.1158/1535-7163.MCT-05-0425.
Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340(15):1144-53. doi: 10.1056/NEJM199904153401502.
Zhou J, Zhang Y, Zou X, Kuai L, Wang L, Wang J, et al. Aberrantly expressed Timeless regulates cell proliferation and cisplatin efficacy in cervical cancer. Hum Gene Ther. 2020;31(5-6):385-95. doi: 10.1089/hum.2019.080.
Ahn WS, Bae SM, Huh SW, Lee JM, Namkoong SE, Han SJ, et al. Necrosis-like death with plasma membrane damage against cervical cancer cells by photodynamic therapy. Int J Gynecol Cancer. 2004;14(3):475-82. doi: 10.1111/j.1048-891x.2004.14308.x.
de Freitas LM, Soares CP, Fontana CR. Synergistic effect of photodynamic therapy and cisplatin: A novel approach for cervical cancer. J Photochem Photobiol B. 2014;140:365-73. doi: 10.1016/j.jphotobiol.2014.08.021.
Crescenzi E, Varriale L, Iovino M, Chiaviello A, Veneziani BM, Palumbo G. Photodynamic therapy with indocyanine green complements and enhances low-dose cisplatin cytotoxicity in MCF-7 breast cancer cells. Mol Cancer Ther. 2004;3(5):537-44.
Ge R, Ahn JC, Shin JI, Bahk CW, He P, Chung PS. An in vitro and in vivo study of combination therapy with Photogem®-mediated photodynamic therapy and cisplatin on mouse cancer cells (CT-26). Photomed Laser Surg. 2011;29(3):155-60. doi: 10.1089/pho.2009.2750.
Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011;11(5):325-37. doi: 10.1038/nrc3038.
Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309-14. doi: 10.1126/science.123.3191.309.
Girgis H, Masui O, White NM, Scorilas A, Rotondo F, Seivwright A, et al. Lactate dehydrogenase A is a potential prognostic marker in clear cell renal cell carcinoma. Mol Cancer. 2014;13(1):101. doi: 10.1186/1476-4598-13-101.
Wang J, Wang H, Liu A, Fang C, Hao J, Wang Z. Lactate dehydrogenase A negatively regulated by miRNAs promotes aerobic glycolysis and is increased in colorectal cancer. Oncotarget. 2015;6(23):19456-68. doi: 10.18632/oncotarget.3318.
Koukourakis MI, Giatromanolaki A, Sivridis E, Bougioukas G, Didilis V, Gatter KC, et al. Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer. 2003;89(5):877-85. doi: 10.1038/sj.bjc.6601205.
Okabe K, Hayakawa T, Hamada M, Koike M. Purification and comparative properties of human lactate dehydrogenase isozymes from uterus, uterine myoma, and cervical cancer. Biochemistry. 1968;7(1):79-90. doi: 10.1021/bi00841a011.
Halliwell B, Gutteridge MC. Free radicals in biology and medicine.5th ed. Oxford: Clarendon Press; 2015.
Davies KJ. Protein damage and degradation by oxygen radicals. I. general aspects. J Biol Chem. 1987;262(20):9895-901.
Schumacker PT. Reactive oxygen species in cancer: a dance with the devil. Cancer Cell. 2015;27(2):156-7. doi: 10.1016/j.ccell.2015.01.007.
- Abstract Viewed: 657 times
- PDF Downloaded: 352 times